propafenone has been researched along with Cardiomyopathy, Dilated in 4 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Cardiomyopathy, Dilated: A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The electrophysiologic effects of diprafenone were evaluated in 31 patients (9 X AV nodal reentrant tachycardia, 9 X Wolff-Parkinson-White syndrome, 4 X paroxysmal atrial fibrillation, 10 X recurrent ventricular tachycardia)." | 7.67 | [Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia]. ( Beermann, J; Gerckens, U; Lüderitz, B; Manz, M, 1986) |
| "The electrophysiologic effects of diprafenone were evaluated in 31 patients (9 X AV nodal reentrant tachycardia, 9 X Wolff-Parkinson-White syndrome, 4 X paroxysmal atrial fibrillation, 10 X recurrent ventricular tachycardia)." | 3.67 | [Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia]. ( Beermann, J; Gerckens, U; Lüderitz, B; Manz, M, 1986) |
| "Amiodarone has a more favourable therapeutic profile than flecainide and propafenone in these patients, having less tendency to worsen heart failure." | 2.67 | A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). ( , 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Galasso, PJ | 1 |
| Stanton, MS | 1 |
| Vogel, H | 1 |
| Brakhmann, I | 1 |
| Shmitt, K | 1 |
| Baĭer, T | 1 |
| Valdeker, B | 1 |
| Khilbel, T | 1 |
| Kiubler, V | 1 |
| Manz, M | 1 |
| Beermann, J | 1 |
| Gerckens, U | 1 |
| Lüderitz, B | 1 |
1 trial available for propafenone and Cardiomyopathy, Dilated
| Article | Year |
|---|---|
A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.).
Topics: Amiodarone; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Dose-Response Relationship, Drug; | 1992 |
3 other studies available for propafenone and Cardiomyopathy, Dilated
| Article | Year |
|---|---|
Propafenone-induced peripheral neuropathy.
Topics: Adult; Cardiomyopathy, Dilated; Humans; Male; Neurologic Examination; Paresthesia; Propafenone; Sura | 1995 |
[Anti-arrhythmia agents in heart failure].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; C | 1992 |
[Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle of His; Cardiomyopathy, Dilated; Coronary Diseas | 1986 |